Akitake Mukasa

12PUBLICATIONS
29CO-AUTHORS
Gene and molecular therapyPredictive and prognostic markersMedical infection agents (incl. prions)Radiation therapyCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (12)

|Mar 04, 2026
Histological grade 2 and non-contrast-enhancing phenotype provide prognostic information complementary to DNA methylation classification in TERTp-mutant molecular glioblastomas.

Hiroyuki Sueyoshi, Kenji Fujimoto, Katsumi Fujita

|Dec 19, 2024
Dynamic susceptibility contrast perfusion MRI helps in differentiating double-expressor from non-double-expressor subtypes in primary central nervous system lymphoma.

Goh Sasaki, Hiroyuki Uetani, Jun-Ichiro Kuroda

|Mar 04, 2024
Region-specific DNA hydroxymethylation along the malignant progression of IDH-mutant gliomas.

Taijun Hana, Akitake Mukasa, Masashi Nomura

|Jan 10, 2024
Postoperative disappearance of leptomeningeal enhancement around the brainstem in glioblastoma.

Hirotaka Inoue, Jun-Ichiro Kuroda, Hiroyuki Uetani

|Nov 26, 2022
Bevacizumab beyond Progression for Newly Diagnosed Glioblastoma (BIOMARK): Phase II Safety, Efficacy and Biomarker Study.

Motoo Nagane, Koichi Ichimura, Ritsuko Onuki

|Nov 27, 2021
Glioma Cells Acquire Stem-like Characters by Extrinsic Ribosome Stimuli.

Yuki Shirakawa, Kunimasa Ohta, Shunsuke Miyake

Pageof 2

Frequent Collaborators

3 joint publications

Masashi Nomura

3 joint publications

Shogo Yamamoto

2 joint publications

Hiroyuki Aburatani

2 joint publications

Shigeru Kiryu